entered into a regional licensing agreement with Pfizer Inc. for SPR206, Spero’s intravenously -administered next-generation polymyxin product candidate being developed to treat serious multi-drug resistant Gram-negative infections in the...
Under alicensing agreement with Sperothat was announced in January of 2019, Everest Medicines has exclusive rights to develop, manufacture and commercialize SPR206 inGreater China,South Koreaand certain Southeast Asian countries (the "...